Celyad Oncology SA
EBR:CYAD.BR
Overview | Financials
Company Name | Celyad Oncology SA |
Symbol | CYAD.BR |
Currency | EUR |
Price | 0.563 |
Market Cap | 23,324,302 |
Dividend Yield | 0% |
52-week-range | 0.212 - 1.22 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Georges Rawadi |
Website | https://www.celyad.com |
An error occurred while fetching data.
About Celyad Oncology SA
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer;
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD